Seres Therapeutics Management

Management criteria checks 3/4

Seres Therapeutics' CEO is Eric Shaff, appointed in Jan 2019, has a tenure of 5.33 years. total yearly compensation is $3.16M, comprised of 21.7% salary and 78.3% bonuses, including company stock and options. directly owns 0.089% of the company’s shares, worth €127.95K. The average tenure of the management team and the board of directors is 4.7 years and 7.7 years respectively.

Key information

Eric Shaff

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage	21.7%
CEO tenure	5.3yrs
CEO ownership	0.09%
Management average tenure	4.7yrs
Board average tenure	7.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Eric Shaff's remuneration changed compared to Seres Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$83m
Dec 31 2023	US$3m	US$685k	-US$114m
Sep 30 2023	n/a	n/a	-US$141m
Jun 30 2023	n/a	n/a	-US$153m
Mar 31 2023	n/a	n/a	-US$265m
Dec 31 2022	US$4m	US$662k	-US$250m
Sep 30 2022	n/a	n/a	-US$231m
Jun 30 2022	n/a	n/a	-US$103m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$10m	US$625k	-US$66m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$132m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$3m	US$590k	-US$89m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$76m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	US$2m	US$540k	-US$70m
Sep 30 2019	n/a	n/a	-US$73m
Jun 30 2019	n/a	n/a	-US$78m
Mar 31 2019	n/a	n/a	-US$95m
Dec 31 2018	US$1m	US$435k	-US$99m
Sep 30 2018	n/a	n/a	-US$107m
Jun 30 2018	n/a	n/a	-US$92m
Mar 31 2018	n/a	n/a	-US$92m
Dec 31 2017	US$2m	US$377k	-US$89m

Compensation vs Market: Eric's total compensation ($USD3.16M) is above average for companies of similar size in the German market ($USD715.36K).

Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.

CEO

Eric Shaff (47 yo)

5.3yrs

Tenure

US$3,158,336

Compensation

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Eric Shaff	President	5.3yrs	US$3.16m	0.089% $ 127.9k
Lisa von Moltke	Executive VP & Chief Medical Officer	4.2yrs	US$1.57m	0.011% $ 16.1k
Teresa Young	Executive VP and Chief Commercial & Strategy Officer	3.9yrs	US$1.82m	0.010% $ 14.8k
Marella Thorell	Executive VP & CFO	less than a year	no data	no data
David Ege	Executive VP & Chief Technology Officer	3.6yrs	US$5.32m	0.049% $ 69.8k
Matthew Henn	Executive VP & Chief Scientific Officer	5.3yrs	US$1.67m	0.042% $ 60.0k
Carlo Tanzi	Investor Relations Officer	8.5yrs	no data	no data
Thomas DesRosier	Chief Legal Officer	8yrs	US$1.44m	0.080% $ 114.0k
Caroline Holda	Assistant General Counsel	no data	no data	no data

4.7yrs

Average Tenure

56yo

Average Age

Experienced Management: 1S9's management team is considered experienced (4.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Eric Shaff	President	5.3yrs	US$3.16m	0.089% $ 127.9k
Willard Dere	Independent Director	6.8yrs	US$225.23k	0.021% $ 30.0k
Dennis Ausiello	Independent Director	9.1yrs	US$222.27k	0.15% $ 210.9k
Kurt Graves	Independent Director	8.5yrs	US$219.23k	0.12% $ 168.3k
Richard Kender	Independent Director	9.6yrs	US$232.69k	0.042% $ 60.0k
Mark Wilcox	Member of Scientific Advisory Board	9.3yrs	no data	no data
Andrew Goodman	Member of Scientific Advisory Board	no data	no data	no data
Curtis Huttenhower	Member of Scientific Advisory Board	no data	no data	no data
Paul Biondi	Independent Director	4.2yrs	US$211.73k	0.031% $ 45.0k
Stephen Berenson	Independent Chairman	4.8yrs	US$249.23k	0.0024% $ 3.4k
Robert Jenq	Member of Scientific Advisory Board	no data	no data	no data
Elhanan Borenstein	Member of Scientific Advisory Board	no data	no data	no data

7.7yrs

Average Tenure

62yo

Average Age

Experienced Board: 1S9's board of directors are considered experienced (7.7 years average tenure).

Seres Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Recent updates

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

New minor risk - Financial position

Full year 2023 earnings released: US$0.89 loss per share (vs US$2.32 loss in FY 2022)

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

New major risk - Negative shareholders equity

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.36 (vs US$0.70 loss in 2Q 2022)

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Full year 2022 earnings released: US$2.32 loss per share (vs US$0.71 loss in FY 2021)

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$0.74 profit in 3Q 2021)

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Second quarter 2022 earnings released: US$0.70 loss per share (vs US$0.53 loss in 2Q 2021)

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

First quarter 2022 earnings released: US$0.61 loss per share (vs US$0.39 loss in 1Q 2021)

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Seres Therapeutics, Inc. Announces the Publication in the New England Journal of Medicine of Data from Its Phase 3 ECOSPOR III study evaluating SER-109

Seres Therapeutics, Inc. Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

Seres Therapeutics Announces First Patient Enrolled in Phase 1B Study of SER-155

Third quarter 2021 earnings released: EPS US$0.74 (vs US$0.36 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.53 loss per share (vs US$0.28 loss in 2Q 2020)

Seres Therapeutics, Inc. Announces Topline Results from the Phase 2B ECO-RESET Study Evaluating SER-287 in Patients with Mild-To-Moderate Ulcerative Colitis

Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from Russell 3000E Index

Seres Therapeutics Presents Research from Its Early-Stage Microbiome Therapeutic Oncology Programs At the 2021 American Society of Clinical Oncology (Asco) Annual Meeting

Seres Therapeutics Announces U.S. Food and Drug Administration Clearance of Investigational New Drug for SER-155

Seres Therapeutics, Inc. Presents Data Across Its Broad Microbiome Pipeline Including New 24-Week Data from Ser-109 Phase 3 Ecospor III Study in Recurrent C. Difficile Infection At Digestive Disease Week 2021

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.28 loss in 1Q 2020)

Seres Therapeutics, Inc. Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

Full year 2020 earnings released: US$1.12 loss per share (vs US$1.24 loss in FY 2019)

Revenue beats expectations

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

New 90-day low: €17.40

New 90-day low: €18.80

Seres Therapeutics, Inc. Therapeutics to Present SER-109 Phase 3 Mechanistic Data At Keystone Symposium

Seres Therapeutics, Inc. Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology

New 90-day low: €19.00

New 90-day low: €19.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.36 loss per share

New 90-day high: €28.80

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

Seres Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day high: €27.80

Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting

New 90-day high: €23.60

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team